Literature DB >> 25732366

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Francois H Jacques1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25732366     DOI： 10.1212/01.wnl.0000462309.76486.c5

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.

Authors:  Jean-Baptiste Davion; M Cambron; E Duhin; A Chouraki; A Lacour; P Labauge; C Carra; X Ayrignac; P Vermersch
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

2.  Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study.

Authors:  Paolo Riccio; Rocco Rossano; Marilena Larocca; Vincenzo Trotta; Ilario Mennella; Paola Vitaglione; Michele Ettorre; Antonio Graverini; Alessandro De Santis; Elisabetta Di Monte; Maria Gabriella Coniglio
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-18

3.  Is Exercise Training Beneficial in Progressive Multiple Sclerosis?

Authors:  Lara A Pilutti; Thomas A Edwards
Journal:  Int J MS Care       Date:  2017 Mar-Apr

4.  Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis.

Authors:  Ben J E Raveney; Wakiro Sato; Daiki Takewaki; Chenyang Zhang; Tomomi Kanazawa; Youwei Lin; Tomoko Okamoto; Manabu Araki; Yukio Kimura; Noriko Sato; Terunori Sano; Yuko Saito; Shinji Oki; Takashi Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

Review 5.  Emerging small-molecule treatments for multiple sclerosis: focus on B cells.

Authors:  Aaron Gregson; Kaitlyn Thompson; Stella E Tsirka; David L Selwood
Journal:  F1000Res       Date:  2019-03-01

6.  Prevalence of multiple sclerosis in Cuenca, Ecuador.

Authors:  Edgar Patricio Correa-Díaz; María Angélica Ortiz; Ana María Toral; Fernando Guillen; Enrique Terán; Daniel Ontaneda; María García-Castillo; Carolina Jácome-Sánchez; Germaine Torres-Herrán; Andrés Ortega-Heredia; María Eugenia Buestán; Juan Murillo-Calle; Praneeta Raza; Guillermo Baño
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-10-30

7.  Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns.

Authors:  Zahra Salehi; Rozita Doosti; Masoumeh Beheshti; Ehsan Janzamin; Mohammad Ali Sahraian; Maryam Izad
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

Review 8.  Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.

Authors:  Georgina Flórez-Grau; Irati Zubizarreta; Raquel Cabezón; Pablo Villoslada; Daniel Benitez-Ribas
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

9.  Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.

Authors:  Jinender Kumar; M Janelle Cambron-Mellott; Tom Tencer; Oliver Will; deMauri S Mackie; Kathleen Beusterien
Journal:  Patient Prefer Adherence       Date:  2021-07-08       Impact factor: 2.711
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.